The research and development of new traditional Chinese medicine(TCM)drugs have progressively established a novel system founded on the integration of TCM theory,human experience,and clinical trials(termed the“Three ...The research and development of new traditional Chinese medicine(TCM)drugs have progressively established a novel system founded on the integration of TCM theory,human experience,and clinical trials(termed the“Three Combinations”).However,considering TCM's distinctive features of“syndrome differentiation and treatment”and“multicomponent formulations and complex mechanisms”,current TCM drug development faces challenges such as insufficient understanding of the material basis and the overall mechanism of action and an incomplete evidence chain system.Moreover,significant obstacles persist in gathering human experience data,evaluating clinical efficacy,and controlling the quality of active ingredients,which impede the innovation process in TCM drug development.Network pharmacology,centered on the“network targets”theory,transcends the limitations of the conventional“single target”reductionist research model.It emphasizes the comprehensive effects of disease or syndrome biological networks as targets to elucidate the overall regulatory mechanism of TCM prescriptions.This approach aligns with the holistic perspective of TCM,offering a novel method consistent with TCM's holistic view for investigating the complex mechanisms of TCM and developing new TCM drugs.It is internationally recognized as a“next-generation drug research model”.To advance the research of new tools,methods,and standards for TCM evaluation and to overcome fundamental,critical,and cutting-edge technical challenges in TCM regulation,this consensus aims to explore the characteristics,progress,challenges,applicable pathways,and specific applications of network pharmacology as a new theory,method,and tool in TCM drug development.The goal is to enhance the quality of TCM drug research and development and accelerate the efficiency of developing new TCM products.展开更多
Cancer is recognized as a leading cause of deaths nowadays,accounting for 10 million annual deaths worldwide and resulting in heavy health and economic burdens[1].Reducing cancer incidence through precision prevention...Cancer is recognized as a leading cause of deaths nowadays,accounting for 10 million annual deaths worldwide and resulting in heavy health and economic burdens[1].Reducing cancer incidence through precision prevention is thus of great scientific and clinical value.Gastric cancer(GC)is one of the most common cancers in China.Pathologically,the onset of GC,especially the intestinal-type ones,would usually suffer a series of premalignant lesions,including atrophic gastritis,intestinal metaplasia,and low-grade dysplasia(LGD),which is known as the process of gastritis-induced tumorigenesis(GIGT)[2].Epidemiological studies have shown that GIGT has exhibited the characteristics of longterm and low-probability,that is,only a small number of gastritis patients would develop into GC after a long period.Therefore,it has become the key challenge for GC precision prevention that how to uncover the biological mechanism underlying GIGT,followed by accurately identifying the critical time point at which effective diagnosis and treatment strategies could be developed to prevent GC.Of note,this is also a common challenge for the precision prevention of other cancer types,such as liver and colon cancers.展开更多
基金supported by the National Medical Products Administration Commissioned Research Project (No.20211440216)the National Administration of Traditional Chinese Medicine Science and Technology Project (No.GZY-KJS-2024-03)+3 种基金the State Key Laboratory of Drug Regulatory Science Project (No.2023SKLDRS0104)the Basic Research Program Natural Science Fund-Frontier Leading Technology Basic Research Special Project of Jiangsu Province (No.BK20232014)the Programs Foundation for Leading Talents in National Administration of Traditional Chinese Medicine of China“Qihuang scholars”Projectthe Tianjin Administration for Market Regulation Science and Technology Key Projects (No.2022-W35)。
文摘The research and development of new traditional Chinese medicine(TCM)drugs have progressively established a novel system founded on the integration of TCM theory,human experience,and clinical trials(termed the“Three Combinations”).However,considering TCM's distinctive features of“syndrome differentiation and treatment”and“multicomponent formulations and complex mechanisms”,current TCM drug development faces challenges such as insufficient understanding of the material basis and the overall mechanism of action and an incomplete evidence chain system.Moreover,significant obstacles persist in gathering human experience data,evaluating clinical efficacy,and controlling the quality of active ingredients,which impede the innovation process in TCM drug development.Network pharmacology,centered on the“network targets”theory,transcends the limitations of the conventional“single target”reductionist research model.It emphasizes the comprehensive effects of disease or syndrome biological networks as targets to elucidate the overall regulatory mechanism of TCM prescriptions.This approach aligns with the holistic perspective of TCM,offering a novel method consistent with TCM's holistic view for investigating the complex mechanisms of TCM and developing new TCM drugs.It is internationally recognized as a“next-generation drug research model”.To advance the research of new tools,methods,and standards for TCM evaluation and to overcome fundamental,critical,and cutting-edge technical challenges in TCM regulation,this consensus aims to explore the characteristics,progress,challenges,applicable pathways,and specific applications of network pharmacology as a new theory,method,and tool in TCM drug development.The goal is to enhance the quality of TCM drug research and development and accelerate the efficiency of developing new TCM products.
基金supported by the National Natural Science Foundation of China(T2341008,62061160369,and 81225025).
文摘Cancer is recognized as a leading cause of deaths nowadays,accounting for 10 million annual deaths worldwide and resulting in heavy health and economic burdens[1].Reducing cancer incidence through precision prevention is thus of great scientific and clinical value.Gastric cancer(GC)is one of the most common cancers in China.Pathologically,the onset of GC,especially the intestinal-type ones,would usually suffer a series of premalignant lesions,including atrophic gastritis,intestinal metaplasia,and low-grade dysplasia(LGD),which is known as the process of gastritis-induced tumorigenesis(GIGT)[2].Epidemiological studies have shown that GIGT has exhibited the characteristics of longterm and low-probability,that is,only a small number of gastritis patients would develop into GC after a long period.Therefore,it has become the key challenge for GC precision prevention that how to uncover the biological mechanism underlying GIGT,followed by accurately identifying the critical time point at which effective diagnosis and treatment strategies could be developed to prevent GC.Of note,this is also a common challenge for the precision prevention of other cancer types,such as liver and colon cancers.
